SuperworthPyxis Oncology PYXS
- Market cap
- $140.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Pyxis Oncology's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | $16.1M | $0 | $0 | $0 | n/a | $2.8M | $0 | $11M | n/a | $0 | |
| Cost of revenue | n/a | n/a | $475K | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | $15.7M | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $14.7M−23% | $11.6M−61% | $13M+10% | $14M+23% | $17.7M+21% | $14M+21% | $17M+31% | $17.1M+23% | $17.8M+0% | $21.7M+55% | $20M+17% | $16.1M−6% |
| SG&A | $10.7M+14% | $6.2M−24% | $8.2M−9% | $6.1M−10% | $6M−44% | $5.1M−18% | $5.9M−29% | $5.4M−11% | $5.7M−6% | $5.2M+3% | $4.4M−25% | $9.9M+83% |
| −$25.4M−11% | −$17.8M−53% | −$5.6M−73% | −$20M+11% | −$23.8M−6% | −$40.1M+126% | −$22.9M+309% | −$19.8M−1% | −$23.5M−1% | −$18.3M−54% | −$24.4M+6% | −$26M+32% | |
| Pre-tax income | n/a | n/a | n/a | −$17.3M | −$21.2M | −$37.7M | n/a | −$18.1M+5% | −$22M+4% | −$17M−55% | n/a | −$25.3M+40% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $283K | $0 | $1.1M | n/a | $0 | |
| Net income | −$23M−17% | −$15.6M−57% | −$3.3M−83% | −$17.3M+9% | −$21.2M−8% | −$35.6M+128% | −$21.2M+550% | −$18.4M+6% | −$22M+4% | −$18.1M−49% | −$23.3M+10% | −$25.3M+38% |
| −$0.56−34% | −$0.35−66% | −$0.06−89% | −$0.29−29% | −$0.35−38% | −$0.58+66% | −$0.35+483% | −$0.30+3% | −$0.35+0% | −$0.29−50% | −$0.37+6% | −$0.40+33% | |
| 41.3M+27% | 44.4M+28% | 51.3M+45% | 60.5M+58% | 60.7M+47% | 61.2M+38% | 61M+19% | 61.9M+2% | 62.6M+3% | 63M+3% | 63.5M+4% | 64M+3% |
Gross profit: 4 periods, Q1 FY24 to Q4 FY24: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Pyxis Oncology's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PYXSPyxis Oncology | $140.1M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
More on Pyxis Oncology
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .